Zobrazeno 51 - 60
of 87
pro vyhledávání: '"BUZDAR, A"'
Publikováno v:
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 22(6)
After analysis using HPLC and electronic ion spray mass spectroscopy, the purified siderophore produced by the marine-derived Aureobasidium pullulans HN6.2 was found to be fusigen. The purified desferric fusigen still had strong inhibition of growth
Autor:
Miriam Hatsue Honda Federico, Pamela Rennie, John F.R. Robertson, Aman U. Buzdar, Luis Fein, Adam Brufsky, Elizabeth S. Lowe, Frédéric Amant, Stephen Chia, Francisco Sapunar, Martine Piccart, Louis Mauriac, Kurt Possinger, Gilles Romieu, José Bines, William J. Gradishar
Publikováno v:
Journal of clinical oncology, 26(10), 1664-1670. American Society of Clinical Oncology
Purpose The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor–positive (HR+) breast cancer. Because many patients subsequently experience
Autor:
Aman U. Buzdar, Allen S. Melemed, Patrick Peterson, Vijaya Laxmi Deshmane, Savitri Krishnamurthy
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(31)
Purpose To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer. Patients and Methods Women with estrogen- or progesterone-receptor–positive breast cancer who had not received prior sys
Autor:
Aman U. Buzdar
Publikováno v:
Breast disease. 24
Tamoxifen has provided the mainstay of endocrine therapy for more than 20 years. However, the development of the third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, has provided an alternative strategy for managing hor
Autor:
Aysegul A. Sahin, Eric A. Strom, Richard L. Theriault, Vicente Valero, Aman U. Buzdar, Gabriel N. Hortobagyi, William M. Sikov, Edgardo Rivera, Lajos Pusztai, Massimo Cristofanilli, Daniel J. Booser, Cynthia Carter, Terry K. Smith, Debra Frye, Kelly K. Hunt, W. Fraser Symmans, Marguerite F. Rosales, Nuhad K. Ibrahim, Marjorie C. Green
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(25)
Purpose To determine the impact a change in schedule of paclitaxel administration from once every 3 weeks to frequent administration would have on the pathologic complete response (pCR) rate in the breast and lymph nodes for patients with invasive br
Autor:
A. U. Buzdar
Publikováno v:
Breast Cancer Online. 7
Endocrine therapy is now established as the treatment option of choice for postmenopausal women with hormone receptor-positive advanced breast cancer. The benefit of the third-generation aromatase inhibitors (AIs) in this setting has prompted their e
Autor:
Kristine Broglio, Yuko Yamamura, Massimo Cristofanilli, Shu Wan Kau, Nour Sneige, Aman U. Buzdar, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Vicente Valero
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(18 Pt 1)
Purpose: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. Nuclear expression of p53 protein in breast cancer correlates with more aggressive tumors. We retrospectively analyze the expression of p53 as a prognostic mark
Autor:
L D O Richard Theriault, Aman U. Buzdar, Paolo Morandi, Gabriel Hortobagyi, Roman Rouzier, Kadri Altundag
Publikováno v:
Cancer. 101(7)
BACKGROUND The authors examined the published evidence on the use of aromatase inhibitors (AIs) in the adjuvant setting in postmenopausal, hormone receptor–positive patients, and they provide recommendations for clinical management in 3 different s
Autor:
Aman U. Buzdar, Kellie L. Jones
Publikováno v:
Endocrine-related cancer. 11(3)
Breast cancer is the most common carcinoma diagnosed in women today excluding non-melanoma skin cancers. It has been well documented that estrogen plays a critical role in its development and is a major target for treatment. For many years, tamoxifen
Autor:
Aman U. Buzdar
Publikováno v:
Clinical breast cancer. 4
Recent advances have been made in the hormonal treatment of breast cancer with the advent of third- generation aromatase inhibitors (anastrozole, letrozole, and exemestane). These newer agents have substantial antitumor activity and appear to be as e